Zinc-finger nucleases for somatic gene therapy: the next frontier - PubMed (original) (raw)
Review
Zinc-finger nucleases for somatic gene therapy: the next frontier
Shamim H Rahman et al. Hum Gene Ther. 2011 Aug.
Abstract
Zinc-finger nucleases (ZFNs) are a powerful tool that can be used to edit the human genome ad libitum. The technology has experienced remarkable development in the last few years with regard to both the target site specificity and the engineering platforms used to generate zinc-finger proteins. As a result, two phase I clinical trials aimed at knocking out the CCR5 receptor in T cells isolated from HIV patients to protect these lymphocytes from infection with the virus have been initiated. Moreover, ZFNs have been successfully employed to knockout or correct disease-related genes in human stem cells, including hematopoietic precursor cells and induced pluripotent stem cells. Targeted genome engineering approaches in multipotent and pluripotent stem cells hold great promise for future strategies geared toward correcting inborn mutations for personalized cell replacement therapies. This review describes how ZFNs have been applied to models of gene therapy, discusses the opportunities and the risks associated with this novel technology, and suggests future directions for their safe application in therapeutic genome engineering.
Figures
FIG. 1.
Zinc-finger nuclease-mediated DNA cleavage. (A) Architecture of a zinc-finger nuclease (ZFN) subunit. A ZFN subunit encompasses three to six zinc-fingers arranged in a tandem array (depicted here is a three-finger array) and the catalytic domain of the _Fok_I endonuclease. A short linker connects the two domains. (B) ZFN target site. The target site is composed of the two target half-sites, which are separated by a short DNA spacer. (C) After dimerization of the two ZFN subunits, the nuclease is activated and cuts the DNA within the spacer sequence, leaving a 5′-overhang. (D) ZFN off-target activity. Insufficient specificity of DNA-binding permits ZFN binding to and cleaving at unintended DNA sites. Color images available online at
FIG. 2.
Zinc-finger nuclease mediated genome editing. (A) Targeted gene disruption. A DNA double-strand break (DSB) introduced by a ZFN is repaired by the error-prone nonhomologous end-joining (NHEJ) pathway. The resulting insertions and deletions at the cleavage site can disrupt the coding sequence by inserting frameshift or nonsense mutations (m), leading to a functional knockout. (B) Targeted deletion. A targeted chromosomal deletion can be achieved if two DSBs are created simultaneously by two pairs of ZFNs at two adjacent sites on a chromosome. (C) Gene correction. A genetic defect in the genome is restored by co-introducing ZFN with a donor DNA that encompasses wild-type sequences homologous to the mutated gene (Xm). The ZFN-induced DSB stimulates homology-directed repair (HDR) between the donor DNA and the defective gene. (D) Gene complementation by targeted integration into a safe harbor. In order to restore the phenotype of a cell harboring a genetic defect, a therapeutic expression cassette (V) flanked by sequences homologous to the safe harbor locus is embedded into a donor DNA. The ZFN-induced DSB stimulates HDR and results in targeted integration of the therapeutic gene. Color images available online at
Similar articles
- Zinc-finger nuclease based genome surgery: it's all about specificity.
Händel EM, Cathomen T. Händel EM, et al. Curr Gene Ther. 2011 Feb;11(1):28-37. doi: 10.2174/156652311794520120. Curr Gene Ther. 2011. PMID: 21182467 Review. - Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.
Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. Holt N, et al. Nat Biotechnol. 2010 Aug;28(8):839-47. doi: 10.1038/nbt.1663. Epub 2010 Jul 2. Nat Biotechnol. 2010. PMID: 20601939 Free PMC article. - Progress and prospects: zinc-finger nucleases as gene therapy agents.
Carroll D. Carroll D. Gene Ther. 2008 Nov;15(22):1463-8. doi: 10.1038/gt.2008.145. Epub 2008 Sep 11. Gene Ther. 2008. PMID: 18784746 Free PMC article. Review. - Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly.
Kim HJ, Lee HJ, Kim H, Cho SW, Kim JS. Kim HJ, et al. Genome Res. 2009 Jul;19(7):1279-88. doi: 10.1101/gr.089417.108. Epub 2009 May 21. Genome Res. 2009. PMID: 19470664 Free PMC article. - Biological and biomedical applications of engineered nucleases.
Pan Y, Xiao L, Li AS, Zhang X, Sirois P, Zhang J, Li K. Pan Y, et al. Mol Biotechnol. 2013 Sep;55(1):54-62. doi: 10.1007/s12033-012-9613-9. Mol Biotechnol. 2013. PMID: 23089945 Review.
Cited by
- Precise genome-editing in human diseases: mechanisms, strategies and applications.
Zheng Y, Li Y, Zhou K, Li T, VanDusen NJ, Hua Y. Zheng Y, et al. Signal Transduct Target Ther. 2024 Feb 26;9(1):47. doi: 10.1038/s41392-024-01750-2. Signal Transduct Target Ther. 2024. PMID: 38409199 Free PMC article. Review. - Guanidyl-Rich Poly(β Amino Ester)s for Universal Functional Cytosolic Protein Delivery and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas9 Ribonucleoprotein Based Gene Editing.
Wang X, Li Y, Wang X, Sandoval DM, He Z, A S, Sáez IL, Wang W. Wang X, et al. ACS Nano. 2023 Sep 26;17(18):17799-17810. doi: 10.1021/acsnano.3c03269. Epub 2023 Sep 5. ACS Nano. 2023. PMID: 37669145 Free PMC article. - A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.
Zittersteijn HA, Harteveld CL, Klaver-Flores S, Lankester AC, Hoeben RC, Staal FJT, Gonçalves MAFV. Zittersteijn HA, et al. Front Genome Ed. 2021 Feb 4;2:617780. doi: 10.3389/fgeed.2020.617780. eCollection 2020. Front Genome Ed. 2021. PMID: 34713239 Free PMC article. Review. - A primer to gene therapy: Progress, prospects, and problems.
Zittersteijn HA, Gonçalves MAFV, Hoeben RC. Zittersteijn HA, et al. J Inherit Metab Dis. 2021 Jan;44(1):54-71. doi: 10.1002/jimd.12270. Epub 2020 Jul 20. J Inherit Metab Dis. 2021. PMID: 32510617 Free PMC article. Review. - The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases.
Mohammadi Pour P, Fakhri S, Asgary S, Farzaei MH, Echeverría J. Mohammadi Pour P, et al. Front Pharmacol. 2019 Nov 8;10:1207. doi: 10.3389/fphar.2019.01207. eCollection 2019. Front Pharmacol. 2019. PMID: 31787892 Free PMC article. Review.
References
- Alwin S. Gere M.B. Guhl E., et al. Custom zinc-finger nucleases for use in human cells. Mol. Ther. 2005;12:610–617. - PubMed
- Benabdallah B.F. Allard E. Yao S., et al. Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. Cytotherapy. 2010;12:394–399. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials